Wahome, E., Otieno, F.O., Kimani, J., Boyd, A., Okall, D., Nzioka, J., Gichuru, E., van der Elst, E., Mehta, S.D., Bailey, R.C. and Graham, S.M., 2022. Impact of COVID-19-related clinic closures on HIV incidence in a multicentre study of young adult MSM and transgender women in Kenya. AIDS, pp.10-1097.
Chihota, V., Gombe, M., Gupta, A., Salazar-Austin, N., Ryckman, T., Hoffmann, C.J., LaCourse, S., Mathad, J.S., Mave, V., Dooley, K.E. and Chaisson, R.E., 2024. Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review. Drugs, pp.1-21.
Shewamene, Z., Belachew, M., Shiferaw, A., De Groot, L., Sahlie, M., Gadissa, D., Abdurhman, T., Bedru, A., Leta, T., Dube, T. and Deyanova, N., 2024. Facilitators and barriers to uptake of digital adherence technologies in improving TB care in Ethiopia: A qualitative study. PLOS Digital Health, 3(11), p.e0000667.
White, R.G., Fiore-Gartland, A.J., Hanekom, W.A., Vekemans, J., Garcia-Basteiro, A.L., Churchyard, G., Rangaka, M.X., Frick, M., Behr, M.A., Hill, P.C. and Mave, V., 2024. What is next for BCG revaccination to prevent tuberculosis?. The Lancet Respiratory Medicine, 12(3), pp.e7-e8.
Jerome, R.N., Zahn, L.A., Abner, J.J., Joly, M.M., Shirey-Rice, J.K., Wallis, R.S., Bernard, G.R. and Pulley, J.M., 2024. Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective. Translational Gastroenterology and Hepatology, 9.
Wand, H., Naidoo, S., Govender, V., Reddy, T. and Moodley, J., 2024. Preventing Stunting in South African Children Under 5: Evaluating the Combined Impacts of Maternal Characteristics and Low Socioeconomic Conditions. Journal of Prevention, 45(3), pp.339-355.
Moodie, Z., Andersen-Nissen, E., Grunenberg, N., Dintwe, O.B., Omar, F.L., Kee, J.J., Bekker, L.G., Laher, F., Naicker, N., Jani, I. and Mgodi, N.M., 2024. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. Plos Medicine, 21(3), p.e1004360.
Fwambah, L., Andisi, C., Streatfield, C., Bromell, R., Hare, J., Esbjörnsson, J., Ndung’u, T., Sanders, E.J., Hassan, A.S. and Nduati, E., 2024. Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya. Frontiers in Immunology, 14, p.1283559.
